Lumicitabine (ALS-008176) is an inhibitor of RSV polymerase.

In an adult human challenge study, Lumicitabine has shown efficacy against RSV infection[1]. Lumicitabine solubility is adequate to support oral administration in solutions with a relatively low percentage of organic solvent and in aqueous suspensions. High levels of NMP and NTP are obtained following the oral administration of Lumicitabine to monkeys [2].

Rats: Lumicitabine is formulated as solutions in PEG400-based vehicles. Pharmacokinetic studies are conducted at 5 mg/kg and for oral PK studies, the prodrugs are administered at 5 mg/kg parent nucleoside equivalent doses. Blood samples are typically collected at various time points up to 24 h post dose for rat [2]. Monkeys: Lumicitabine is formulated as a solution in PEG400-based vehicles. Pharmacokinetic studies are conducted at 5 mg/kg and for oral PK studies, the prodrugs are administered at 5 mg/kg parent nucleoside equivalent doses. Blood samples are typically collected at various time points up to 12 h post dose for Monkeys [2].